Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ocrelizumab versus rituximab for refractory generalized myasthenia gravis
ChiCTR2400084422Phase 2Completed
- Sponsor
- Peking University People's Hospital
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in generalized myasthenia gravis (gMG) comparing Ocrelizumab group with Rituximab group (2 arms). Primary endpoints: Change in QMG score from baseline to Week 24, Change in MG-QOL15r score from baseline to Week 24 and 1 more. Started May 2024; status: completed.
02
Drugs
ocrelizumabrituximab
03
Conditions
generalized myasthenia gravis (gMG)
Beyond the preview
Go deeper on ChiCTR2400084422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084422.